


PCT/GB 99 / 03 180

22 SEPTEMBER 1999
INVESTOR IN PEOPLE

Patent
Office

GB 99/3180

Best Available Copy



The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

**PRIORITY
DOCUMENT**
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

Signed

Andrew Gensy

Dated

22 OCT 1999

THIS PAGE IS BLANK

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form))

The Patent Office

Cardiff Road
Newport
Gwent NP9 1RH

1. Your reference

P.75353 GCW/PJC

2. Patent application number
(The Patent Office will fill in this part)

9820658.4

3. Full name, address and postcode of the or of each applicant (underline all surnames)

MEDICAL RESEARCH COUNCIL
20 Park Crescent
London W1N 4AL

Patents ADP number (if you know it)

596067001

If the applicant is a corporate body, give the country/state of its incorporation

United Kingdom



4. Title of the invention

"TREATMENT OF INFECTION"

5. Name of your agent (if you have one)

J A KEMP & CO

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

14 SOUTH SQUARE
GRAY'S INN
LONDON WC1R 5LX

Patents ADP number (if you know it)

26001

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number

Country

Priority application number
(if you know it)

Date of filing
(day / month / year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing
(day / month / year)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer "Yes" if:

YES

- a) any applicant named in part 3 is not an inventor, or
 - b) there is an inventor who is not named as an applicant, or
 - c) any named applicant is a corporate body:
- See note (d))

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form

Description 33

Claim(s) 2

Abstract 1

Drawing(s) 2

+ 2 SS

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (Patents Form 7/77)

Request for preliminary examination and search (Patents Form 9/77)

Request for substantive examination (Patents Form 10/77)

Any other documents (please specify)

11.

I/We request the grant of a patent on the basis of this application

Signature

J. A. Kemp + Co

Date

22/09/98

12. Name and daytime telephone number of person to contact in the United Kingdom

G.C. WOODS
0171 405 3292

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue of a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered "Yes" Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

TREATMENT OF INFECTION

Field of the invention

5 This invention relates to inhibitors of the expression and activity of a gene product and screening methods for the identification of such inhibitors. It further relates to the use of said inhibitors in the treatment of infection by an organism, such as a malaria parasite.

10

Background to the invention

The malaria parasite and related Apicomplexans are unusual amongst non-photosynthetic organisms in that they possess two forms of organellar DNA, typically a property of plants. One form of organellar DNA is mitochondrial DNA and the other is a 35 kb circle of DNA present in a plastid. The plastid is thought to be of prokaryotic origin. The *ycf 24* gene^{1,2} which is present on the DNA of this plastid corresponds to a well conserved gene which is also found in red algal plastids³ and various bacteria, including *E. coli*.

20 The plastid genome of Apicomplexans⁴ is distinctive from, but broadly resembles that of the parasitic higher plant *Epifagus virginiana*⁵. It has been suggested that the *raison d'etre* for maintenance of vestigial plastid genomes is the small number of open reading frames they carry besides the highly selected set of genes dedicated to the organellar expression system⁶. Unlike

30 Apicomplexans, *Epifagus* does not carry the *ycf 24* gene on its plastid genome, suggesting that either the vestigial organelles have different functions, or a stochastic process determines gene loss or transfer to the nucleus.

The high level of conservation of *ycf 24* (~50% amino acid identity of the putative encoded peptide product with other orthologs) suggests that it is under strong

35

selective pressure and likely to have a general function.

Organelle transfection is not available in Apicomplexans. Therefore "knockouts" can only be tested in surrogate organisms.

5

Summary of the invention

The present inventors have disrupted *ycf 24* in both *Synechocystis* sp. strain pCC6803 and *E. coli*⁷.

10 Disruption of all the copies of the *ycf 24* gene in these organisms was found to be lethal. Disruption of some of the copies of *ycf 24* was found to give a 'ragged' phenotype in *Synechocystis* and appeared to cause a delay in or interfere in the process of septation during cell division. Thus *ycf 24* is an essential gene and appears to
15 play a role in replication. The present invention is based on the inhibition of the expression or activity of the *ycf 24* product to inhibit the growth of an organism in vivo or ex vivo.

20 Thus the invention provides an inhibitor of *ycf 24* gene product expression and/or activity for use in a method of treatment of the human or animal body by therapy. Such an inhibitor is useful in particular in the treatment of infection by an organism, such as a malaria parasite. The invention also provides a method of
25 inhibiting the growth of an organism comprising contacting the organism ex vivo with an inhibitor of *ycf 24* gene product expression and/or activity.

30 ~~Screens may be carried out to identify the~~ inhibitor. Accordingly the invention provides a method of identifying a compound that inhibits the growth of an organism comprising
(i) contacting a test compound with the *ycf 24* gene product, and
(ii) determining whether the test compound inhibits the

activity of or binds to the product, any such binding or inhibition being indicative that the compound inhibits the growth of the organism.

5 The invention also provides a method of identifying a compound that inhibits the growth of an organism comprising

(i) contacting a test compound with a test construct comprising a *ycf 24* promoter operably linked to a coding sequence,

10 (ii) determining whether the test compound inhibits expression driven by the promoter, any such inhibition being indicative that the compound inhibits the growth of the organism.

The invention further provides a pharmaceutical composition comprising an inhibitor of the invention and a pharmaceutically acceptable carrier or diluent.

15 As noted above the inhibitor may be used to treat an infection by an organism and therefore the invention provides a method of treating a host suffering from an infection by an organism, which method comprises administering to the host a therapeutically effective amount of an inhibitor of *ycf 24* product expression and/or activity.

25 Brief description of the drawings

The invention is illustrated by the accompanying drawings in which:

Fig.1 shows phenotypic characters of wild type (WT), ragged transformant (R) and smooth mutant forms (S) of *Synechocystis* sp. : a) Colony shape and size; an enlargement is inserted in R, b) Scanning electron micrographs of whole cells - bar = 10µm, c) Cross-sections showing plaques - arrow, d) Whole cells with and without DAPI-staining. Arrows point to mis-segregation.

35 Fig.2 shows a Southern blot of DNA from

Synechocystis sp., restricted with *Hind* III and hybridized with wild type (WT) *ycf* 24. The sizes expected for restriction fragments from WT (lane 4) and clones of heteroplasmic transformants (lanes 1-3) are given in the diagram below.

Detailed description of the invention

The inhibitor can be used to inhibit the growth of a unicellular or multicellular organism in vivo or ex vivo. The organism may be a prokaryote or a eukaryote. The organism comprises the *ycf* 24 gene. In the case of a eukaryote the nuclear genome of the organism may contain the *ycf* 24 gene or the organism may contain an organelle which contains DNA comprising the *ycf* 24 gene. Such an organelle is generally of prokaryotic origin, for example algal origin, and may be a plastid.

The organism may be a protozoa, such as an Apicomplexan, for example of clade plasmodium, piroplasm, sarcocystan or coccidium. The organism may be *Plasmodium falciparum*. The organism may be an alga. The organism may be a bacterium, such as a cyanobacterium, mycobacterium or *E. coli*. The organism may be free-living or a pathogen of humans and/or animals. It may be an intracellular or extracellular pathogen.

The *ycf* 24 gene product is generally one which can be expressed from the coding region of:
(a) the polynucleotide sequence of SEQ ID NO: 1, 2 or 3 or a fragment thereof; or

(b) polynucleotides which can selectively hybridise to the coding region of (a) or a fragment thereof; or
(c) polynucleotides which, but for the degeneracy of the genetic code, would hybridise to (a) or (b).

The polynucleotides of (b) may selectively hybridise under conditions of medium to high stringency, for example 0.03M NaCl and 0.03M sodium citrate at from 50 to

60 degrees centigrade.

Thus the polynucleotide from which the *ycf 24* product is expressed generally has at least 70%, preferably at least 95, 97 or 99% sequence identity to the coding sequence of SEQ ID NO: 1, 2, or 3 over a region of at least 20, preferably at least 30, for instance at least 46, 60 or 100 or more contiguous nucleotides.

The *ycf 24* product generally has at least 50% sequence identity to the amino acid sequences shown is SEQ ID NO: 1, 2, or 3, preferably at least 80 or 90% and more preferably at least 95, 97 or 99% over a region of at least 20, preferably at least 30, for instance at least 46, 60, 100 or more contiguous amino acids. The term *ycf 24* product includes fragments of the amino acid sequences of SEQ ID NO: 1, 2 or 3 or of the homologous sequences discussed above. Suitable fragments will be at least 5, 10, 20 or 40 amino acids in size, for example at least 60 or 100 amino acids in size. Generally the *ycf 24* product has *ycf 24* product activity, and would generally be able to complement the activity of a naturally occurring *ycf 24* product.

Any suitable inhibitor of *ycf 24* product activity may be used in the present invention. The inhibitor may bind in a reversible or irreversible manner. An irreversible inhibitor would dissociate very slowly from the *ycf 24* product because it would be very tightly bound, either covalently or non-covalently. Reversible binding, in contrast with irreversible binding, is characterised by a rapid dissociation of the *ycf 24* product-inhibitor complex.

As noted above the invention provides a method of identifying a compound that inhibits the activity of *ycf 24* product. *ycf 24* product for use in this method can

be obtained, for example, recombinantly by any method known in the art. The nucleotide sequences of the *ycf 24* genes of *Plasmodium falciparum*, *Synechocystis* Sp strain pCC6803 and *E.coli* are provided herein as SEQ ID NOs 1, 2
5 and 3 respectively. The *ycf 24* genes of other species may be identified by searching in databases for genes homologous to SEQ ID NO: 1, 2 or 3. Nucleotides with the same sequence as genes identified in a database can be made and expressed using routine methods which are known
10 in the art. Alternatively *ycf 24* genes can be identified by probing genomic or cDNA libraries with nucleotides comprising the *ycf 24* gene or a fragment of the *ycf 24* gene and then isolating and sequencing the nucleotides identified by the probe.

15 Any suitable format may be used for identifying the inhibitor of the activity. In the method the *ycf 24* product is generally in a suitable buffer, which includes any suitable biological buffer that can provide buffering capability at a pH conducive to the reaction requirements
20 of the *ycf 24* product. The *ycf 24* product may be in conditions which are similar to the physiological conditions in which it occurs naturally.

In the method the *ycf 24* product may be in inside a cell or outside a cell. The cell may be the cell in which
25 the *ycf 24* product naturally occurs, or a cell in which the *ycf 24* product is expressed recombinantly. The cell may be treated with agents which permeabilise the cell surface allowing test substances to enter the cell more
readily. The *ycf 24* product used in the method may be in
30 the form of an extract from such cells.

The method may determine whether a test compound is able to bind the *ycf 24* product, such as in a specific manner. This method may comprise allowing the *ycf 24* product to bind to a test compound and measuring the

amount of binding that occurs, such as by measuring the amount of *ycf 24* bound to the compound. The amount of binding may be determined by measuring a characteristic of the *ycf 24* product that changes upon binding, such as spectroscopic changes.

The assay format may be a 'band shift' system. This involves determining whether a test compound advances or retards the *ycf 24* product on gel electrophoresis relative to the *ycf 24* product in the absence of the compound.

The method may be a competitive binding assay. This determines whether the test compound is able to inhibit the binding of the *ycf 24* product to a substance which is known to bind to the *ycf 24* product, such as an antibody specific for product. This method allows test compounds to be identified which are 'analogues' of *ycf 24* product.

The competitive binding system may comprise
(i) incubating the *ycf 24* product with a test compound and a labelled reference compound that is known to bind the product;

(ii) determining the amount of the labelled reference compound that is bound to the product; and

(iii) comparing the amount of bound labelled reference compound determined in step (ii) with the amount of said compound that binds to the product in the absence of the test compound;

wherein any reduction in the binding of the labelled reference compound in the presence of the test compound compared to the binding in the absence of the test

compound shows that the test compound is competing with the reference compound for binding to the product. This indicates that the test compound could be an inhibitor of *ycf 24* product activity.

The amount of the labelled reference compound bound to the *ycf 24* product may be measured directly or

indirectly. A direct measurement may be carried out by removing assay mixture containing the unbound labelled reference compound and measuring the amount of label that is in the product fraction. Alternatively, the amount of
5 labelled reference compound bound to the product could be determined indirectly by measuring the amount of label remaining in the assay solution after removal of the product fraction, which will be inversely related to the amount that has bound to the product.

10 In a competitive binding assay system, the *ycf 24* product may be immobilised on a solid support or may be in solution. The use of immobilised product has the advantage that, after the binding reaction is complete, the product/labelled reference compound complex may be
15 separated from the labelled reference compound that remains in solution by simply removing the solution away from the solid support. If, on the other hand, the product is not immobilised during the assay but rather is in solution, then it will generally be necessary to
20 devise a means for separating the product/labelled reference compound complex from the uncomplexed reference compound before measuring the amount of label. Such separation could be achieved, for example, by precipitating the product using an antibody to the
25 product or by using a non-specific precipitation technique.

Suitable labels for use in the assay systems according the invention are well-known in the art. The
reference compound which is know to bind the *ycf 24*
30 product may be an antibody.

An antibody to *ycf 24* product may be produced by raising antibody in a host animal against the whole
ycf 24 product or an antigenic epitope thereof (hereinafter "the immunogen"). Methods of producing
35 monoclonal and polyclonal antibodies are well-known. A

method for producing a polyclonal antibody comprises immunising a suitable host animal, for example an experimental animal, with the immunogen and isolating immunoglobulins from the serum. The animal may therefore
5 be inoculated with the immunogen, blood subsequently removed from the animal and the IgG fraction purified. A method for producing a monoclonal antibody comprises immortalising cells which produce the desired antibody. Hybridoma cells may be produced by fusing spleen cells
10 from an inoculated experimental animal with tumour cells (Kohler and Milstein, Nature 256, 495-497, 1975).

An immortalized cell producing the desired antibody may be selected by a conventional procedure. The hybridomas may be grown in culture or injected
15 intraperitoneally for formation of ascites fluid or into the blood stream of an allogenic host or immunocompromised host. Human antibody may be prepared by *in vitro* immunisation of human lymphocytes, followed by transformation of the lymphocytes with Epstein-Barr
20 virus.

For the production of both monoclonal and polyclonal antibodies, the experimental animal is suitably a goat, rabbit, rat or mouse. If desired, the immunogen may be administered as a conjugate in which the immunogen is
25 coupled, for example via a side chain of one of the amino acid residues, to a suitable carrier. The carrier molecule is typically a physiologically acceptable carrier. The antibody obtained may be isolated and, if
desired, purified.

30 Any suitable inhibitor of expression of *ycf 24* product may be employed in the present invention. Preferably the inhibitor is a specific inhibitor of transcription from the *ycf 24* gene, and does not inhibit transcription from other genes.

35 The inhibitor may inhibit transcription or

translation of *ycf 24* product. The inhibitor may bind to the *ycf 24* gene either 5' to the coding sequence, to the coding sequence or 3' to the coding sequence. Thus the inhibitor may bind to the *ycf 24* promoter, and inhibit
5 the initiation of transcription. The inhibitor may bind and inhibit the action of a protein which is required for transcription from the *ycf 24* gene. The inhibitor may bind to the untranslated or translated regions of the *ycf 24* mRNA. This could prevent the initiation of
10 translation. Alternatively the inhibitor could bind to a protein which associates with the untranslated region and prevent the protein associating with the untranslated region.

Any suitable assay format may be used for
15 identifying an inhibitor of *ycf 24* expression. The invention provides a method for identifying an inhibitor of *ycf 24* expression comprising:
(i) contacting a compound with a nucleic acid comprising a *ycf 24* promoter operably linked to a coding sequence; and
20 (ii) determining whether the compound inhibits expression driven by the promoter.

Generally this method is carried out in conditions which in the absence of the test compound lead to expression of the coding sequence from the nucleic acid.
25 The nucleic acid may also comprise other untranscribed or untranslated regions of the *ycf 24* gene. The coding sequence typically encodes a protein that is able to act as a reporter of expression. The assay may be carried
out in a cell which harbours the nucleic acid. The
30 substance may be tested with any other known promoter to test the possibility that the test substance is a general inhibitor of gene expression.

Any reporter polypeptide may be used, for example GUS or GFP. GUS is assayed by measuring the hydrolysis
35 of a suitable substrate, for example 5-bromo-4-chloro-3-

indolyl- β -D-glucuronic acid (X-gluc) or 4-methylumbelliferyl- β -glucuronide (MUG). The hydrolysis of MUG yields a product which can be measured fluorometrically. GFP is quantified by measuring fluorescence at 590nm after excitation at 494nm. These methods are well known to those skilled in the art.

Alternatively the coding sequence may be the *ycf 24* coding sequence itself, or a fragment of this sequence. The expression of the *ycf 24* product may be measured by for example, Northern/RNA blotting, Western/antibody blotting, RNA in situ hybridization or immunolocalisation. Thus the method for identifying an inhibitor of expression of *ycf 24* product may be performed on a cell which naturally harbours the *ycf 24* gene, or an extract from such a cell.

Suitable candidate substances which may be inhibitors and which can be tested in the methods discussed above include antibody products (for example, monoclonal and polyclonal antibodies, single chain antibodies, chimeric antibodies and CDR-grafted antibodies) which are specific for *ycf 24* product. Furthermore, combinatorial libraries, defined chemical identities, peptide and peptide mimetics, oligonucleotides and natural product libraries, such as display libraries (e.g. phage display libraries) may also be tested. The candidate substances may be chemical compounds. Batches of the candidate substances may be used in an initial screen of, for example, ten substances per reaction, and the substances of batches which show inhibition tested individually.

Antisense inhibitors

As noted above the expression of *ycf 24* in a cell may be reduced by the presence in that cell of a compound which can bind to the *ycf 24* mRNA. Therefore a polynucleotide

which is capable of hybridizing to *ycf 24* mRNA can constitute an appropriate inhibitor of *ycf 24* expression.

The polynucleotide may be antisense to the *ycf 24* mRNA. Such a polynucleotide may be capable of
5 hybridising to *ycf 24* mRNA and may thus inhibit the expression of *ycf 24* product by interfering with one or more aspects of *ycf 24* mRNA metabolism including processing, translation and metabolic turnover.

The antisense polynucleotide may be RNA. This may
10 hybridise to the *ycf 24* mRNA to form an RNA-RNA duplex which may cause direct inhibition of translation and/or the destabilization of the target message, for example, rendering susceptibility to nucleases.

Such a polynucleotide may hybridize to all or part
15 of the *ycf 24* mRNA. Typically the antisense polynucleotide hybridizes to the ribosome binding region or the coding region of the *ycf 24* mRNA. The polynucleotide may be complementary to all of or a region of the *ycf 24* mRNA. For example, the polynucleotide may
20 be the exact complement of all or a part of *ycf 24* mRNA. However, absolute complementarity is not required and polynucleotides which have sufficient complementarity to form a duplex having a melting temperature of greater than 20°C, 30°C or 40°C under physiological conditions are
25 particularly suitable for use in the present invention. The polynucleotide may be a polynucleotide which hybridises to the *ycf 24* mRNA under conditions of medium to high stringency such as 0.03M sodium chloride and
30 0.03M sodium citrate at from about 50 to about 60 degrees centigrade.

It is preferred that the polynucleotide hybridizes to all or part of the region of the *ycf 24* mRNA corresponding to the coding sequence defined by nucleotides 26 to 1435 of SEQ ID NO:1. However, the

polynucleotide may hybridise to all or part of the 5'- or 3'-untranslated region of the mRNA. The polynucleotide will typically be from 6 to 40 nucleotides in length.

Preferably it will be from 12 to 20 nucleotides in length. The polynucleotides may be at least 40, for example at least 60 or at least 80, nucleotides in length and up to 100, 200, 300, 400, 500, 600 or 700 nucleotides in length or even up to a few nucleotides, such as five or ten nucleotides, shorter than SEQ ID NO: 1, 2 or 3.

When the polynucleotide is an antisense RNA it may be expressed in a cell from a recombinant replicable vector. Such a replicable vector comprises a polynucleotide which when transcribed gives rise to antisense RNA.

Thus the antisense polynucleotide may be provided by delivering such a vector to the cell and allowing transcription from the vector to occur. Such a vector is also understood to an inhibitor of *ycf 24* expression in this specification. Generally on the vector the polynucleotide giving rise to the antisense RNA is operably linked to a control sequence which is capable of providing for the transcription of the polynucleotide giving rise to the antisense RNA. The term "operably linked" refers to a juxtaposition wherein the components described are in a relationship permitting them to function in their intended manner. A control sequence "operably linked" to a sequence giving rise to an antisense RNA is ligated in such a way that transcription of the sequence is achieved under conditions compatible with the control sequences.

The vector may be for example, a plasmid or virus vector provided with an origin of replication, optionally a promoter for transcription to occur and optionally a regulator of the promoter. The vector may contain one or more selectable marker genes, for example an ampicillin

resistance gene in the case of bacterial plasmid or a neomycin resistance gene for a mammalian vector. Vectors may be used in vitro, for example for the production of antisense RNA or used to transfect or transform a host cell. The term 'host cell' refers either to the organism whose growth it is desired to inhibit, or a human or animal cell which can be infected by the organism. Thus the host cell may be an infected cell. The vector may also be adapted to be used in vivo, for example in a method of gene therapy.

Promoters/enhancers and other expression regulation signals may be selected to be compatible with the host cell for which the expression vector is designed. For example, mammalian promoters, such as b-actin promoters, may be used. Tissue-specific promoters, in particular neuronal cell specific promoters (for example the tyrosine hydroxylase (TH), L7, or neuron specific enolase (NSE) promoters), are especially preferred. Viral promoters may also be used, for example the Moloney murine leukaemia virus long terminal repeat (MMLV LTR), the rous sarcoma virus (RSV) LTR promoter, the SV40 promoter, the human cytomegalovirus (CMV) IE promoter, herpes simplex virus promoters or adenovirus promoters. All these promoters are readily available in the art. Preferred promoters are tissue specific promoters such as the casein gene promoter.

The vector may further include sequences flanking the polynucleotide giving rise to antisense RNA which comprise sequences homologous to eukaryotic genomic sequences, preferably mammalian genomic sequences, or viral genomic sequences. This will allow the introduction of the polynucleotides of the invention into the genome of eukaryotic cells or viruses by homologous recombination. In particular, a plasmid vector comprising the expression cassette flanked by viral sequences, for example HSV1 or

HSV2 sequences, can be used to prepare a viral vector, for example an HSV vector, suitable for delivering the polynucleotides of the invention to a mammalian cell.

Other examples of suitable viral vectors include

5 retroviruses, including lentiviruses, adenoviruses and adeno-associated viruses. Gene transfer techniques using these viruses are known to those skilled in the art. Retrovirus vectors for example may be used to stably integrate the polynucleotide giving rise to the antisense
10 RNA into the host genome. Replication-defective adenovirus vectors by contrast remain episomal and therefore allow transient expression.

Antisense polynucleotides may be chemically modified. This may enhance their resistance to nucleases and may
15 enhance their ability to enter cells. For example, phosphorothioate oligonucleotides may be used. Other deoxynucleotide analogs include methylphosphonates, phosphoramidates, phosphorodithioates, N3'P5'-phosphoramidates and oligoribonucleotide phosphorothioates
20 and their 2'-O-alkyl analogs and 2'-O-methylribonucleotide methylphosphonates.

Alternatively mixed backbone oligonucleotides (MBOs) may be used. MBOs contain segments of phosphothioate oligodeoxynucleotides and appropriately placed segments of
25 modified oligodeoxy- or oligoribonucleotides. MBOs have segments of phosphorothioate linkages and other segments of other modified oligonucleotides, such as methylphosphonate, which is non-ionic, and very resistant to nucleases or 2'-O-alkyloligoribonucleotides.

30 An inhibitor of *ycf 24* expression and/or activity is one which produces a measurable reduction in *ycf 24* expression and/or activity in the methods described above. Preferred substances are those which inhibit *ycf 24* expression and/or activity by at least 10%, at least 20%,
35 at least 30%, at least 40% at least 50%, at least 60%, at

least 70%, at least 80%, at least 90%, at least 95% or at least 99% at a concentration of the inhibitor of $1\mu\text{g ml}^{-1}$, $10\mu\text{g ml}^{-1}$, $100\mu\text{g ml}^{-1}$, $500\mu\text{g ml}^{-1}$, 1mg ml^{-1} , 10mg ml^{-1} or 100mg ml^{-1} . The percentage inhibition represents the percentage decrease in expression/activity in a comparison of assays in the presence and absence of the test substance. Any combination of the above mentioned degrees of percentage inhibition and concentration of inhibitor may be used to define an inhibitor of the invention, with greater inhibition at lower concentrations being preferred.

When used in vivo or in vitro the inhibitor inhibits the growth of the organism. Generally the inhibitor will decrease the rate of cell division of the organism. Generally the inhibitor will decrease the number of divisions that occur in a unit of time by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or 100% at a concentration of inhibitor of $1\mu\text{g ml}^{-1}$, $10\mu\text{g ml}^{-1}$, $100\mu\text{g ml}^{-1}$, $500\mu\text{g ml}^{-1}$, 1mg ml^{-1} , 10mg ml^{-1} or 100mg ml^{-1} .

If the organism is one in which the *ycf 24* gene is present in an organelle then the inhibitor generally decreases the rate of division of that organelle. The inhibitor may also disrupt cell or organelle division in other ways, such as causing abnormal septation or mis-segregation of DNA. The inhibitor may also disrupt the structure of the organism, such as giving the organism a 'ragged' appearance. The inhibitor may cause the death of the organism.

Candidate substances which show activity in assays such as those described herein can then be tested on the organism in question. The inhibitor may or may not be toxic towards humans or animals. The inhibitor may thus be used as an antibiotic.

The inhibitors of *ycf 24* expression and/or activity or the vectors described above may be used to treat infections by an organism and, in particular, malaria. The

condition of a patient suffering from an infection can therefore be improved by administration of such an inhibitor. A therapeutically effective amount of such an inhibitor may be given to a human patient in need thereof.

5 The formulation of inhibitor or vector for use in preventing or treating infection by an organism will depend upon factors such as the nature of the substance identified, whether a pharmaceutical or veterinary use is intended, etc. In order to be administered to a patient,
10 the compound will be provided in the form of a pharmaceutical composition containing the inhibitor or vector and a pharmaceutically acceptable carrier or diluent. Suitable carriers and diluents include isotonic saline solutions, for example phosphate-buffered saline.
15 Typical oral dosage compositions include tablets, capsules, liquid solutions and liquid suspensions. For example it may be formulated for parenteral, intravenous, intramuscular, subcutaneous, transdermal or oral administration.

20 The dose of inhibitor may be determined according to various parameters, especially according to the substance used; the age, weight and condition of the patient to be treated; the route of administration; and the required regimen. A physician will be able to determine the
25 required route of administration and dosage for any particular patient. A suitable dose may however be from 0.1 to 100 mg/kg body weight such as 1 to 40 mg/kg body weight, for example, to be taken from 1 to 3 times daily.

30 The oral route is preferred because this is generally the most convenient route for a patient to take regular doses of the compound without the assistance of a physician. However, the inhibitor or vector may be administered by direct injection into the site to be treated.

35 The inhibitor or vector may be used in either the

treatment of an existing infection by the organism or in the prevention of such an infection from occurring in the first place.

5 The vectors giving rise to antisense RNA of the invention may be administered directly as a naked nucleic acid construct. Uptake of naked nucleic acid constructs by mammalian cells is enhanced by several known transfection techniques, for example those including the use of transfection agents. Example of these agents include
10 cationic agents (for example calcium phosphate and DEAE-dextran) and lipofectants (for example lipofectamTM and transfectamTM). These agents may also enhance the uptake of the constructs by the organism.

15 The pharmaceutical composition may be formulated to aid delivery of the inhibitor or vector to the organism whose growth is to be inhibited. In particular it may be formulated to deliver the inhibitor or vector to the cell type which is infected or to the compartment in the human or animal cell which is infected by the organism. It may be
20 formulated to deliver the inhibitor or vector to the organelle in the organism where *ycf 24* product or mRNA is present.

When the pharmaceutical composition comprises viral vector for gene therapy it may be administered in such a
25 way that the vector is incorporated into cells at an appropriate area. The amount of virus administered is in the range of from 10^4 to 10^8 pfu, preferably from 10^5 to 10^7 pfu, more preferably about 10^6 pfu for herpes viral vectors
and from 10^6 to 10^{10} pfu, preferably from 10^7 to 10^9 pfu,
30 more preferably about 10^8 pfu for adenoviral vectors. When injected, typically 1-2 ml of virus in a pharmaceutically acceptable suitable carrier or diluent is administered. When the polynucleotide is administered as a naked nucleic acid, the amount of nucleic acid administered is typically
35 in the range of from 1 μ g to 10 mg.

Where the polynucleotide giving rise to the antisense RNA is under the control of an inducible promoter, it may only be necessary to induce gene expression for the duration of the treatment. Once the condition has been treated, the inducer is removed and expression of the polypeptide of the invention ceases. This will clearly have clinical advantages. Such a system may, for example, involve administering the antibiotic tetracycline, to activate gene expression via its effect on the tet repressor/VP16 fusion protein.

The use of tissue-specific promoters will be of assistance in the treatment of disease using the vectors of the invention. It will be advantageous to be able express inhibitors of *ycf 24* in only the relevant affected cell types, especially where such inhibitors are toxic when expressed in other cell types.

When the inhibitor is used to inhibit the growth of an organism *ex vivo* the organism may or may not be a pathogen of humans or animals. The inhibitor may be used to treat land, water or food containing the organism.

The following Examples illustrate the invention:

Example 1

Gene disruption of *ycf 24*, transformation and selection

A central segment of the wild type gene (*slr0074*) from *Synechocystis* sp., strain pCC6803, (delineated by two *HindIII* sites ~1.0 kb apart) was amplified from genomic DNA by PCR using two oligonucleotide primers based on the known sequence (Accession no. S76598): 5' CTC CGC CCC TAA GCA AAG TAA GGA A and 5' TGA TCC TCG CCA ATT TTG GAA GTG GA. The amplified fragment was restricted with *HindIII* and cloned into pUC9 to give pUC9/*slr*. The sequence of both ends of the insert was confirmed in recombinants grown in *Epicurian* SURE cells. To disrupt the gene, a kanamycin resistance gene (*k^r*) isolated from a modified bluescript

vector (pBSHdSpl, was blunt-ended with the Klenow fragment and cloned into a unique *Xba*I site in the *ycf* 24 insert to give pUC9/*slr*/*k^r*. Recombinants in XL1-blue MRF' cells were selected using kanamycin. Disruption of the *ycf* 24 insert was confirmed by sequencing the junction regions.

Wild type (WT) cells of *Synechocystis* sp. strain PCC 6803 were transfected by incubation with light at 30°C for 4 hr with vector DNA carrying the disrupted *ycf* 24 gene (1-5 µg in 10 µl water). Selection and growth were carried out on BG11 plates under photo-autotrophic conditions at 30°C. Several rounds of replication were allowed over 3 days before recombinants were selected by overlaying with kanamycin (50 µg/ml). This killed most of the cells but transformants emerged after a delay. Every 10-14 days thereafter, transformants were picked and re-plated to allow segregation of mutant cells. For growth comparisons in the absence of selection, WT cells were plated at the same time on BG11 (their growth was inhibited totally by kanamycin at 50 µg/ml).

Example 2

Gene Disruption in *E. coli*

Disruption of *ycf* 24 in *E. coli* was carried out along similar lines, but in this case disruption was with the *aadA* gene for streptomycin resistance (*S^r*). *ycf* 24 from *E. coli* was amplified using primers based on the accession no. D90811 with added terminal restriction sites: 5' GAG CTC GGA ATT CGC ATG TGG CGA AAG and 3' GAG CTC GGG ATC CGA CGC TGT GTT CAA G. The *E. coli* *aadA* gene was introduced at a *Bsg*I restriction site near the centre of *ycf* 24 and cloned into the bluescript vector pBSKS⁺. The construct was linearized for transformation and to allow homologous recombination in *E. coli* INValphaF' One Shot cells. The linearized recombinant plasmid pBSKS⁺/*ycf*24/*S^r* was

transfected into *E. coli* by heat shock but no homologous recombinants were found; a few antibiotic resistant colonies were recovered that carried circular episomes likely to have arisen from re-ligation of the construct.

5

Example 3

Characterising the *Synechocystis* transformants

WT *Synechocystis* and transfectants carrying an homologous form of *ycf* 24 interrupted by a kanamycin resistance gene (*k^r*) were plated on BG-11 agar. The WT cells formed colonies visible to the naked eye within 4 days, whereas it took 2 weeks for transformants to appear under selection with kanamycin (50 $\mu\text{g ml}^{-1}$). Colonies of transformants were small and "ragged" in outline in contrast to the larger, smooth-contoured WT colonies (Fig. 1a). DNA extracted from cloned transformants was hybridized in Southern blots with WT *ycf* 24 and found to be heteroplasmic, the copy numbers of the disrupted and WT forms of *ycf* 24 being approximately equal as judged from the intensity of the hybridization signals (Fig. 2). Relaxation of kanamycin selection on heteroplasmic transformants resulted in vigorously growing, smooth-contoured colonies - "revertants", confirming that the heteroplasmic state was growth-limiting. These observations were confirmed by additional transformations, including one using disruption with a spectinomycin resistance gene instead of kanamycin. Transformants homoplasmic for the disrupted form of *ycf* 24 were never recovered, even after prolonged selection with kanamycin at 50 or 100 $\mu\text{g ml}^{-1}$ and homoplasmy is inferred to be lethal.

Longer-term selection of "ragged" transformants on kanamycin also gave rise to rapidly growing colonies with smooth contours. However, hybridization on Southern blots showed these remained heteroplasmic for the disrupted gene and we refer to these as "smooth" suppressors. DNA from

35

cloned "smooth" suppressors was used to transform both WT and "ragged" heteroplasmic cells. In both cases, kanamycin selection yielded mostly "ragged" colonies but small numbers (<1%) of smooth, rapidly growing colonies were found, unlike in the original transfections.

The cells were examined by electron microscopy. Pelleted cells were pre-fixed in 0.5% neutral glutaraldehyde in 100mM cacodylate buffer, pH 7.0 for 30 min at room temperature. After gentle centrifugation, the pelleted cells were fixed in 2-3% glutaraldehyde buffer and thin sections were prepared using standard procedures. For scanning electron microscopy (SEM), cells were spread on glass slips coated in poly-L-lysine (100 $\mu\text{g ml}^{-1}$) and fixed in 2% glutaraldehyde. Post fixation samples were washed in ethanol and rehydrated by immersion in hexamethyl-

disilazane. After overnight dessication, samples were sputter-coated with 20 nm gold (for sample conductivity) and examined by SEM.

Electron micrographic sections showed ~80% of cells from "ragged" colonies (>100 cells examined) had electron-translucent plaques surrounding the phycobilisomes in the thylacoid membranes (Fig. 1c). The number of cells containing plaques fell to ~45% upon relaxation of kanamycin selection pressure, coincident with reversion to normal colony morphology. Because similar plaques were found in ~4% WT cells, we suggest they indicate "sick" cells rather than a direct phenotypic change following disruption of *ycf 24*.

By contrast, examination of the gross morphology of cells from "ragged" colonies by scanning electron microscopy showed a significant accumulation of cells (~50%) in the last stages of cell division ($p = <0.001$), suggesting a defect in cytokinesis (Table 1 and Fig.1b). Relaxation of kanamycin selection again saw the proportion of dividing cells in the transformed cell population return

to one resembling WT . A high proportion (~60%) of the "smooth" suppressor cells also accumulated at a late stage of cytokinesis, with occasional small chains of incompletely separated cells. Smooth suppressors still contained electron-opaque plaques and electron micrographic sections confirmed that suppression increased the frequency of aberrant septation in dividing cells.

Table 1

10

		% Fission			
	Cell type ^{*1}	Early stage	Late stage	Total	P (X ²) ^{*3}
15	WT	10	9±1	19	-
	Ragged	21 ±6	34±1	55	<0.001
	Revertant ^{*2}	8	4	12	0.9
	Smooth	20	41	61	<0.001

^{*1} Nos. cells counted = >100/group (mean data from 2 exp.)

^{*2} Ragged transformants grown without kanamycin selection

20 ^{*3} Chi-square comparison with WT

DNA was stained with 4',6-diamindino-2-phenylindole (DAPI) at 0.01µg ml⁻¹, following a protocol similar to that described¹⁵. When stained with DAPI, the nucleoids of WT cells were highly uniform in appearance (Fig.1d). Most WT cells (~82%) were not in division and only a few dead cells (unstained) were present. DAPI-staining of cells from

"ragged colonies" was much more variable, ranging from cells that looked like WT to a large number (~50%) of dead or dying cells that stained less intensely. The latter included >50% of those in division. Although nucleoid segregation had occurred in many of these cells, in ~40% the DNA had mis-segregated (ie. one daughter cell was without DNA or carried less DNA as judged by staining

30

intensity); altered autofluorescence under UV light indicated these were dying cells. DAPI-stained "smooth" suppressants also were distinctive. About half of the cells (both dividing and non-dividing) carried normal amounts of DNA but occasional cells either had no DNA (~1% dead), had undergone asymmetric DNA segregation (~1%), or had about twice as much DNA (~1%) as WT. The cells in this last group were larger than the rest (Fig. 1d). Coulter counter analysis of the size distribution of the different populations (data not shown) confirmed that the numbers of small and large cells had substantially increased in both the "ragged" and smooth isolates compared with WT. The amount of DNA per cell corresponded generally with cell size, excepting dead cells.

Example 4

Over-expression of ycf 24 in *E.coli*

The effect of over-expressing ycf 24 in *E. coli* also was examined using into the expression vector pMAL-c2. Gene amplification was carried out with primers designed to give a 5' *Eco* RI site and a 3' *Pst* I site, and the product was cloned into the pMAL-c2 and p2 expression vectors (New England Biolabs). Cultures of transfectants growing exponentially in Terrific broth containing ampicillin (50 $\mu\text{g ml}^{-1}$) were induced with 0.5 mM IPTG. Transformants expressing fusion proteins after induction at 37°C with IPTG were detected by Western blotting.

Filamentation was marked in such transformants. The gene was also over-expressed in the periplasmic expression vector pMAL-p2. One such transformant over-expressed a soluble, truncated fusion protein causing stasis of cultures within 1 hr at 37°C and cell death. The fusion protein appeared to have a C-terminal deletion.

Conclusions

We conclude that disruption of *ycf 24* in *Synechocystis* sp., by homologous recombination is lethal, except in cells with a heteroplasmic genotype; these nevertheless have severely impaired colony growth. The ragged appearance (sectoring) attributed to cell death is not likely to be due to loss of k^+ by segregation as this does not occur following its random insertion into the genome. Accumulation of heteroplasmic cells at a late stage in cytokinesis, suggests delayed or incomplete septation and many "dividing cells" died. DAPI-staining also showed mis-segregation and loss of DNA. This finding contrasts with the only other *ycf 24* knockout we know of, recorded in the Cyanomutant database, where no phenotype was observed. It is possible this difference is related to our finding that revertants emerged rapidly upon relaxation of kanamycin selection, and that "smooth" suppressor mutants also emerged under continuous kanamycin selection. Smooth suppressants are presumed to be the result of compensatory mutation(s), the character(s) being transformable and able to confer viability to heteroplasmic transformants without restoring them to WT. The multiple-septation evident in "smooth" suppressants may be in keeping with their rapid growth rate⁸, but asymmetric septation also occurred resulting in small chains of deformed cells.

Over-expression of *ycf 24* in *E. coli* also blocked cytokinesis. The possibility that this was elicited by the SOS response⁹ remains to be investigated, but cytoplasmic expression, unlike periplasmic expression, did not cause

cell death over a period of 2-3 hr after induction. Interestingly, *ycf 24* carries an intein in some species of mycobacteria¹⁰, a feature long known of some genes concerned with DNA regulation (eg. *recA* and DNA polymerase¹¹).

Database searches with the putative peptide encoded by *ycf 24* for homologies with proteins of known function

showed no significant "hits", but protein folding motifs were found (using the programme THREADER¹²) with significant homology to those of an O-glycosyl hydrolase - namely, alpha amylase.

5 It follows from our observations that *ycf 24*, an essential house-keeping gene essential at a late stage of the prokaryotic cell cycle, is not the *raison d'etre* of the vestigial apicomplexan plastid genome, ie. it does not encode the primary function. Yet retention of *ycf 24* on
10 this highly degenerate plastid genome can be reconciled with the necessity for strict control of DNA segregation and plastid replication. In the parasites examined so far, each cell carries a single plastid with only a few copies of the 35 kb plastid genome - estimates are ~1-3
15 copies/cell in *P. falciparum*, whereas *Toxoplasma gondii* has >5 copies¹³. Replication of plastid DNA in apicomplexans is essential for cell survival and has been shown to be vulnerable to antibiotic interference^{13,14}.

References

1. Williamson, D.H., et al. *Mol. Gen. Genet.* **243**, 249-252(1994).
- 5 2. Denny, P., Preiser, P., Williamson, D. & Wilson, I. *Protist* **1**, 51-59 (1998).
3. Kowallik, K.V., Stoebe, B., Schaffran, I., Kroth-Pancic, P. & Freier, U. *Plant Mol. Report.* **13**, 336-342 (1995).
- 10 4. Wilson, R.J.M., et al. *J. Mol. Biol.* **261**, 155-172 (1996).
5. Palmer, J.D. *Nature* **364**, 762-763 (1993).
6. Wolfe, K.H., Morden, C.W. & Palmer, J.D. *Proc. Natl. Acad. Sci.* **89**, 10648-10652 (1992).
- 15 7. Labarre, J., Chauvat, F. & Thuriaux, P. *J. Bacteriol.* **171**, 3449-3457 (1989).
8. Paulton, R.J.L. *J. Bacteriol.* **104**, 762-767 (1970).
9. Walker, G.C. *The SOS response of Escherichia coli.* In *Escherichia coli and Salmonella Cellular and Molecular Biology*. Vol.1 pp.1400-1416. (ASM Press, Washington D.C.) (1997).
- 20 10. Pietrokovski, S. *Prot. Sci.* **3**, 2340-2350 (1994).
11. Colston, M.J. & Davies, E.O. *Mol. Microbiol.* **12**, 359-363 (1994).
- 25 12. Jones, D.T., Taylor, W.R. & Thornton, J.M. *Nature* **358**, 86-89 (1992).
13. Fichera, M.E. & Roos, D.S. *Nature* **390**, 407-409 (1997).
14. McFadden, G.I. & Waller, R.F. *Bioessays* **19**, 1033-1040 (1997).
- 30 15. Hiraga, S., et al. *J. Bacteriol.* **171**, 1496-1505 (1989).

SEQUENCE LISTING

SEQ ID NO:1

<210> 5
<211> 1444
<212> DNA
<213> Plasmodium falciparum
<221> CDS
<222> (26)..(1435)
<400> 5

tttattatattt ttatatataa ttatt atg ata aaa tta aaa aat ttt tta aat	52
Met Ile Lys Leu Lys Asn Phe Leu Asn	
1 5	
att tat aat tta aat tat aaa tat caa tat aaa aat aaa ata aat tta	100
Ile Tyr Asn Leu Asn Tyr Lys Tyr Gln Tyr Lys Asn Lys Ile Asn Leu	
10 15 20 25	
tat tta ata aga caa gga tta aat ata aat tta ata aaa aat tta tct	148
Tyr Leu Ile Arg Gln Gly Leu Asn Ile Asn Leu Ile Lys Asn Leu Ser	
30 35 40	
agt aat att ttt tta tat atg ttt att tat aat ttt aaa aaa tat tct	196
Ser Asn Ile Phe Leu Tyr Met Phe Ile Tyr Asn Phe Lys Lys Tyr Ser	
45 50 55	
tta aaa tta tta aat ata ttt aaa tta cct gat tgg aat ttt ttt gat	244
Leu Lys Leu Leu Asn Ile Phe Lys Leu Pro Asp Trp Asn Phe Phe Asp	
60 65 70	
tgt cca aat ata aat tat gat aat att att tat tat tct tct att tta	292
Cys Pro Asn Ile Asn Tyr Asp Asn Ile Ile Tyr Tyr Ser Ser Ile Leu	
75 80 85	
aaa gat aat aat tta ata tat tat tta aaa aat aat tta aat att gaa	340
Lys Asp Asn Asn Leu Ile Tyr Tyr Leu Lys Asn Asn Leu Asn Ile Glu	
90 95 100 105	
ttt tta gat agt ata tta ata aaa aat aat tct ata gat att ata ttt	388
Phe Leu Asp Ser Ile Leu Ile Lys Asn Asn Ser Ile Asp Ile Ile Phe	
110 115 120	
gat agt atg tct att tta cat act aca caa tat ttt tta aaa aaa tta	436
Asp Ser Met Ser Ile Leu His Thr Thr Gln Tyr Phe Leu Lys Lys Leu	
125 130 135	
gga ata att ttt tta cct tta ttt gat att ata ttt aaa tat cct tta	484
Gly Ile Ile Phe Leu Pro Leu Phe Asp Ile Ile Phe Lys Tyr Pro Leu	
140 145 150	
tta ata aaa aaa tat tta ggt act att att tct tat aaa gat aat ttt	532
Leu Ile Lys Lys Tyr Leu Gly Thr Ile Ile Ser Tyr Lys Asp Asn Phe	
155 160 165	
ttt gct aat att aat tca ata ata ttt agt gaa gga tct ttt tgt tat	580
Phe Ala Asn Ile Asn Ser Ile Ile Phe Ser Glu Gly Ser Phe Cys Tyr	
170 175 180 185	
ata cct aaa tat gta aag tgt aat ttt aat tta tca aca tat ttt aaa	628
Ile Pro Lys Tyr Val Lys Cys Asn Phe Asn Leu Ser Thr Tyr Phe Lys	
190 195 200	
act aat tct tct gat ttt gca caa ttt gaa cgt act tta ata ata gtt	676
Thr Asn Ser Ser Asp Phe Ala Gln Phe Glu Arg Thr Leu Ile Ile Val	
205 210 215	
ggt aaa tat tct tat gta tca tat tta gaa gga tgt aca gct tca tta	724
Gly Lys Tyr Ser Tyr Val Ser Tyr Leu Glu Gly Cys Thr Ala Ser Leu	
220 225 230	
tat aaa gaa tca caa tta cat gta gct ata gta gaa ata ata gta aaa	772
Tyr Lys Glu Ser Gln Leu His Val Ala Ile Val Glu Ile Ile Val Lys	
235 240 245	
gat tat ggt tat ata aaa tat tat aca tta caa aat tgg tat aga gga	820
Asp Tyr Gly Tyr Ile Lys Tyr Tyr Thr Leu Gln Asn Trp Tyr Arg Gly	
250 255 260 265	

gat tat tta ggt aat ggt ggt tta tat aat ttt aca act aaa cgt ggt	868
Asp Tyr Leu Gly Asn Gly Gly Leu Tyr Asn Phe Thr Thr Lys Arg Gly	
270 275 280	
ata tgt tta aat tat tca aaa tta gat tgg ata caa gtt gaa gta ggt	916
Ile Cys Leu Asn Tyr Ser Lys Leu Asp Trp Ile Gln Val Glu Val Gly	
285 290 295	
tcg att ata aca tgg aaa tac cct tct act att tta aaa ggt aaa ttt	964
Ser Ile Ile Thr Trp Lys Tyr Pro Ser Thr Ile Leu Lys Gly Lys Phe	
300 305 310	
tct att agt aat ttt tat tca ata tct ttt ata tca aat atg caa ata	1012
Ser Ile Ser Asn Phe Tyr Ser Ile Ser Phe Ile Ser Asn Met Gln Ile	
315 320 325	
gct gat act ggt agt aaa atg tat cat ata gga tct tat act aaa agt	1060
Ala Asp Thr Gly Ser Lys Met Tyr His Ile Gly Ser Tyr Thr Lys Ser	
330 335 340 345	
tat ata att tct aaa agt ata tct tta aat aac tca tta aat ata ttt	1108
Tyr Ile Ile Ser Lys Ser Ile Ser Leu Asn Asn Ser Leu Asn Ile Phe	
350 355 360	
aga ggt tta gta tat att aaa cct ttt tca tat aaa tct tat aat tat	1156
Arg Gly Leu Val Tyr Ile Lys Pro Phe Ser Tyr Lys Ser Tyr Asn Tyr	
365 370 375	
act gaa tgt agt tct tta ata ttt ggt aat aat tct tta aca gta act	1204
Thr Glu Cys Ser Ser Leu Ile Phe Gly Asn Asn Ser Leu Thr Val Thr	
380 385 390	
att cct tat ata aaa aat tat aat aat act agt tat gta aaa caa gaa	1252
Ile Pro Tyr Ile Lys Asn Tyr Asn Asn Thr Ser Tyr Val Lys Gln Glu	
395 400 405	
gct ttt gtt tct aaa att gaa ath ata tat tta ttt tta tta atg caa	1300
Ala Phe Val Ser Lys Ile Glu Ile Ile Tyr Leu Phe Leu Leu Met Gln	
410 415 420 425	
cgt ggt tta agt att tca gag tct att tca tta tta att ata ggt ttt	1348
Arg Gly Leu Ser Ile Ser Glu Ser Ile Ser Leu Leu Ile Ile Gly Phe	
430 435 440	
tgt tct gat att tat aat aaa tta ccg ttt gaa ttt aat tta gag ata	1396
Cys Ser Asp Ile Tyr Asn Lys Leu Pro Phe Glu Phe Asn Leu Glu Ile	
445 450 455	
cct ata tta ttt tca tta aaa att aaa gat ata ttt aat taattaaat	1444
Pro Ile Leu Phe Ser Leu Lys Ile Lys Asp Ile Phe Asn	
460 465 470	

Note that 'h' at nucleotide position 1276 of SEQ ID NO:1 may be a,t or c.

SEQ ID NO:2

<210> 3
 <211> 1443
 <212> DNA
 <213> Synechocystis PCC6803
 <221> CDS
 <222> (1)..(1443)
 <400> 3

atg agt tcc acc act gtt aaa aac ctg gtc aac caa ccc tac aaa tat	48
Met Ser Ser Thr Thr Val Lys Asn Leu Val Asn Gln Pro Tyr Lys Tyr	
1 5 10 15	
ggc ttt gtc acc aac att gaa gcg gat gct atc ccc cgt ggt ctg agt	96
Gly Phe Val Thr Asn Ile Glu Ala Asp Ala Ile Pro Arg Gly Leu Ser	
20 25 30	
gaa gac gtg gtg cga ctc att tct gct aag aaa aat gaa ccc gaa ttc	144
Glu Asp Val Val Arg Leu Ile Ser Ala Lys Lys Asn Glu Pro Glu Phe	
35 40 45	

atg ttg gat ttt cgc ctc cgg gcc tac cgg cat tgg ctg acc atg gcg	192
Met Leu Asp Phe Arg Leu Arg Ala Tyr Arg His Trp Leu Thr Met Ala	
50 55 60	
gaa ccc act tgg ccg gcg gtg cat tat ccc ccc att gat tac caa gat	240
Glu Pro Thr Trp Pro Ala Val His Tyr Pro Pro Ile Asp Tyr Gln Asp	
65 70 75 80	
att att tac tac tcc gcc cct aag caa agt aag aaa aaa cta gaa agc	298
Ile Ile Tyr Tyr Ser Ala Pro Lys Gln Ser Lys Lys Lys Leu Glu Ser	
85 90 95	
tta gat gaa gtg gac cca gct ttg ttg gaa acc ttt gaa aaa tta ggg	336
Leu Asp Glu Val Asp Pro Ala Leu Leu Glu Thr Phe Glu Lys Leu Gly	
100 105 110	
att ccc cta tcg gag caa aaa cgt tta agt aat gtg gcg gta gat gcc	384
Ile Pro Leu Ser Glu Gln Lys Arg Leu Ser Asn Val Ala Val Asp Ala	
115 120 125	
att ttt gac agt gtt tcc att ggc aca act ttt aag gaa aag cta gcg	432
Ile Phe Asp Ser Val Ser Ile Gly Thr Thr Phe Lys Glu Lys Leu Ala	
130 135 140	
gaa gac ggg gta att ttc tgt tct att tct gaa gca ttg cag gaa cat	480
Glu Asp Gly Val Ile Phe Cys Ser Ile Ser Glu Ala Leu Gln Glu His	
145 150 155 160	
ccc gac ctg gtg caa aaa tat ttg ggc agt gtg gtg ccc acc gcc gac	528
Pro Asp Leu Val Gln Lys Tyr Leu Gly Ser Val Val Pro Thr Ala Asp	
165 170 175	
aac ttc ttt gcc gcc tta aac tct gct gta ttt agt gac ggt tcc ttt	576
Asn Phe Phe Ala Ala Leu Asn Ser Ala Val Phe Ser Asp Gly Ser Phe	
180 185 190	
gtt ttt att ccc aaa ggg gtg aag tgt ccc atg gaa ttg tcc acc tat	624
Val Phe Ile Pro Lys Gly Val Lys Cys Pro Met Glu Leu Ser Thr Tyr	
195 200 205	
ttc cgc att aat aat ggg gat acg ggg cag ttt gag cgg aca tta att	672
Phe Arg Ile Asn Asn Gly Asp Thr Gly Gln Phe Glu Arg Thr Leu Ile	
210 215 220	
att gcc gaa gaa ggg gct tcc gtt agc tat ttg gaa ggt tgt act gcg	720
Ile Ala Glu Glu Gly Ala Ser Val Ser Tyr Leu Glu Gly Cys Thr Ala	
225 230 235 240	
ccc atg tat gac acc aat caa ctt cat gcg gcg gtg gtg gaa ttg gta	768
Pro Met Tyr Asp Thr Asn Gln Leu His Ala Ala Val Val Glu Leu Val	
245 250 255	
gct cta gat aat gct gac att aaa tat tcc acc gta caa aac tgg tac	816
Ala Leu Asp Asn Ala Asp Ile Lys Tyr Ser Thr Val Gln Asn Trp Tyr	
260 265 270	
gct ggg gac gaa aat ggc aag ggc gga att tac aac ttt gtg act aaa	864
Ala Gly Asp Glu Asn Gly Lys Gly Gly Ile Tyr Asn Phe Val Thr Lys	
275 280 285	
cgg ggt cta tgt aaa gga gtt aat tcc aaa att tcc tgg acc caa gta	912
Arg Gly Leu Cys Lys Gly Val Asn Ser Lys Ile Ser Trp Thr Gln Val	
290 295 300	
gaa acc ggt tcc gcc att acc tgg aaa tac ccc agt tgt gtg cta gtt	960
Glu Thr Gly Ser Ala Ile Thr Trp Lys Tyr Pro Ser Cys Val Leu Val	
305 310 315 320	
ggg gat aat tcc gtc ggg gaa ttc tac tct att gct tta act aac aac	1008
Gly Asp Asn Ser Val Gly Glu Phe Tyr Ser Ile Ala Leu Thr Asn Asn	
325 330 335	
aaa cag caa gct gat acg gga act aaa atg att cac atc ggt aaa aat	1056
Lys Gln Gln Ala Asp Thr Gly Thr Lys Met Ile His Ile Gly Lys Asn	
340 345 350	
acc cgt agt atc att att tcc aaa ggc att tcc gct ggt aat tcc gcc	1104
Thr Arg Ser Ile Ile Ile Ser Lys Gly Ile Ser Ala Gly Asn Ser Ala	
355 360 365	

```

aac agt tac cgg ggt ttg gtg aaa atg gga cct aaa gcc cag ggc gct 1152
Asn Ser Tyr Arg Gly Leu Val Lys Met Gly Pro Lys Ala Gln Gly Ala
370 375 380
cgc aat tat tcc cag tgt gat tcc atg ctc att ggc gat cgg gca gcg 1200
Arg Asn Tyr Ser Gln Cys Asp Ser Met Leu Ile Gly Asp Arg Ala Ala
385 390 395 400
gct aat act ttt ccc tat att caa gtg gac aat aat acc gcc aaa gta 1248
Ala Asn Thr Phe Pro Tyr Ile Gln Val Asp Asn Asn Thr Ala Lys Val
405 410 415
gaa cat gaa gct tcc act tcc aaa att ggc gag gat caa ctc ttt tac 1296
Glu His Glu Ala Ser Thr Ser Lys Ile Gly Glu Asp Gln Leu Phe Tyr
420 425 430
ttt gcc caa cgg gga att tct gag gaa gat gcg gtg tcc atg cta gtc 1344
Phe Ala Gln Arg Gly Ile Ser Glu Glu Asp Ala Val Ser Met Leu Val
435 440 445
agc ggt ttc tgt aag gat gtg cta aac gaa tta ccc atg gaa ttt gcg 1392
Ser Gly Phe Cys Lys Asp Val Leu Asn Glu Leu Pro Met Glu Phe Ala
450 455 460
gcg gag gct gat aaa tta ctg agt ctc aaa cta gaa ggt act gtg ggt 1440
Ala Glu Ala Asp Lys Leu Leu Ser Leu Lys Leu Glu Gly Thr Val Gly
465 470 475 480
taa 1443

```

SEQ ID NO:3

<212> DNA
 <213> Escherichia coli
 <221> CDS
 <222> (1)..(1527)
 <400> 1

```

atg tgg ctg tgg cga aag ctt tgg ggt ata ggc ggt act atg tct cgt 48
Met Trp Leu Trp Arg Lys Leu Trp Gly Ile Gly Gly Thr Met Ser Arg
1 5 10 15
aat act gaa gca act gac gat gtc aaa acc tgg acc ggc ggc ccg ctg 96
Asn Thr Glu Ala Thr Asp Asp Val Lys Thr Trp Thr Gly Gly Pro Leu
20 25 30
aat tat aaa gaa gga ttc ttc acc cag tta gcc acc gat gag ctg gca 144
Asn Tyr Lys Glu Gly Phe Phe Thr Gln Leu Ala Thr Asp Glu Leu Ala
35 40 45
aag ggg ata aac gaa gag gtg gtg cgc gca att tcg gcg aag cgt aat 192
Lys Gly Ile Asn Glu Glu Val Val Arg Ala Ile Ser Ala Lys Arg Asn
50 55 60
gag ccg gag tgg atg ctg gag ttt cgt cta aac gcc tat cgc gca tgg 240
Glu Pro Glu Trp Met Leu Glu Phe Arg Leu Asn Ala Tyr Arg Ala Trp
65 70 75 80
ctg gag atg gaa gaa ccg cac tgg ttg aaa gcg cac tac gac aag ctg 288
Leu Glu Met Glu Glu Pro His Trp Leu Lys Ala His Tyr Asp Lys Leu
85 90 95
aat tat cag gat tac agc tac tac tca gca cca tcg tgc ggt aat tgt 336
Asn Tyr Gln Asp Tyr Ser Tyr Tyr Ser Ala Pro Ser Cys Gly Asn Cys
100 105 110
gac gac act tgc gcg tct gaa cct ggc gcg gtg cag caa act ggc gcg 384
Asp Asp Thr Cys Ala Ser Glu Pro Gly Ala Val Gln Gln Thr Gly Ala
115 120 125
aac gcc ttt tta agt aaa gag gtg gag gcg gcg ttt gag cag ttg ggc 432
Asn Ala Phe Leu Ser Lys Glu Val Glu Ala Ala Phe Glu Gln Leu Gly
130 135 140
gtt ccc gtg cgg gaa ggc aaa gag gtg gcg gtg gat gcc att ttc gac 480
Val Pro Val Arg Glu Gly Lys Glu Val Ala Val Asp Ala Ile Phe Asp
145 150 155 160

```

tca gtt tcg gtt gcc act act tat cgc gaa aaa ctg gcg gag cag gga	528
Ser Val Ser Val Ala Thr Thr Tyr Arg Glu Lys Leu Ala Glu Gln Gly	
165 170 175	
att att ttc tgt tcc ttt ggt gag gcg atc cac gat cac ccg gaa ctg	576
Ile Ile Phe Cys Ser Phe Gly Glu Ala Ile His Asp His Pro Glu Leu	
180 185 190	
gtg cgt aaa tat ctc ggc acc gtg gtg ccg ggg aat gac aac ttc ttt	624
Val Arg Lys Tyr Leu Gly Thr Val Pro Gly Asn Asp Asn Phe Phe	
195 200 205	
gcc gcg ctt aat gcg gcg gta gcc tct gat ggt acg ttt att tat gtg	672
Ala Ala Leu Asn Ala Ala Val Ala Ser Asp Gly Thr Phe Ile Tyr Val	
210 215 220	
cct aaa ggc gtg cgc tgc ccg atg gaa ctt tcc acc tat ttt cgc att	720
Pro Lys Gly Val Arg Cys Pro Met Glu Leu Ser Thr Tyr Phe Arg Ile	
225 230 235 240	
aac gca gaa aaa acc ggg cag ttt gag gcg acc att ctg gtg gcc gac	768
Asn Ala Glu Lys Thr Gly Gln Phe Glu Arg Thr Ile Leu Val Ala Asp	
245 250 255	
gaa gac agc tac gtc agc tac att gaa ggc tgt tcc gct ccg gtg cgt	816
Glu Asp Ser Tyr Val Ser Tyr Ile Glu Gly Cys Ser Ala Pro Val Arg	
260 265 270	
gac agc tat cag tta cac gcg gca gtg gtg gaa gtc atc atc cat aaa	864
Asp Ser Tyr Gln Leu His Ala Ala Val Val Glu Val Ile Ile His Lys	
275 280 285	
aac gcc gag gtg aaa tat tcc acg gta caa aac tgg ttt cct ggc gat	912
Asn Ala Glu Val Lys Tyr Ser Thr Val Gln Asn Trp Phe Pro Gly Asp	
290 295 300	
aac aac acc ggc ggt att ctc aac ttc gtc acc aag cgt gct ttg tgc	960
Asn Asn Thr Gly Gly Ile Leu Asn Phe Val Thr Lys Arg Ala Leu Cys	
305 310 315 320	
gaa ggc gaa aac agc aaa atg tca tgg acg caa tca gaa acc ggg tca	1008
Glu Gly Glu Asn Ser Lys Met Ser Trp Thr Gln Ser Glu Thr Gly Ser	
325 330 335	
gcg att acg tgg aaa tat ccc agc tgc att ttg cgc ggc gat aac tcc	1056
Ala Ile Thr Trp Lys Tyr Pro Ser Cys Ile Leu Arg Gly Asp Asn Ser	
340 345 350	
att ggt gag ttt tac tca gtg gcg ctg acc agc ggt cat cag caa gcg	1104
Ile Gly Glu Phe Tyr Ser Val Ala Leu Thr Ser Gly His Gln Gln Ala	
355 360 365	
gat acc ggc acc aag atg atc cac atc ggt aaa aac acc aaa tcg acc	1152
Asp Thr Gly Thr Lys Met Ile His Ile Gly Lys Asn Thr Lys Ser Thr	
370 375 380	
att atc tcg aaa ggg atc tct gcc gga cat agt cag aac agt tat cgc	1200
Ile Ile Ser Lys Gly Ile Ser Ala Gly His Ser Gln Asn Ser Tyr Arg	
385 390 395 400	
ggc tta gtg aaa atc atg ccg acg gca acc aat gcg cgc aat ttc act	1248
Gly Leu Val Lys Ile Met Pro Thr Ala Thr Asn Ala Arg Asn Phe Thr	
405 410 415	
cag tgc gac tca atg ctg att ggc gct aat tgt ggg gcg cat acc ttc	1296
Gln Cys Asp Ser Met Leu Ile Gly Ala Asn Cys Gly Ala His Thr Phe	
420 425 430	
ccg tat gtt gag tgt cgt aac aat agt gcg caa ctg gaa cac gag gca	1344
Pro Tyr Val Glu Cys Arg Asn Asn Ser Ala Gln Leu Glu His Glu Ala	
435 440 445	
acg aca tca cgt att ggt gaa gat caa ctg ttt tac tgc ctg caa cgc	1392
Thr Thr Ser Arg Ile Gly Glu Asp Gln Leu Phe Tyr Cys Leu Gln Arg	
450 455 460	
ggg atc agc gaa gaa gac gcc atc tcg atg att gtt aac ggt ttc tgc	1440
Gly Ile Ser Glu Glu Asp Ala Ile Ser Met Ile Val Asn Gly Phe Cys	
465 470 475 480	

aaa	gac	gtg	ttc	tcg	gag	ctg	cgc	ttg	gaa	ttt	gcc	gtt	gaa	gca	caa	1488
Lys	Asp	Val	Phe	Ser	Glu	Leu	Pro	Leu	Glu	Phe	Ala	Val	Glu	Ala	Gln	
				485					490					495		
aaa	ctc	ctc	gcc	atc	agt	ctt	gaa	cac	agc	gtc	gga	taa				1527
Lys	Leu	Leu	Ala	Ile	Ser	Leu	Glu	His	Ser	Val	Gly					
			500					505								

Claims

1. An inhibitor of *ycf 24* gene product expression
and/or activity for use in a method of treatment of the
5 human or animal body by therapy.

2. An inhibitor according to claim 1 for use in a
method of treatment of infection by an organism.

10 3. An inhibitor according to claim 2 for use in a
method of treatment of malaria.

4. A method of inhibiting the growth of an
organism comprising contacting the organism ex vivo with an
15 inhibitor of *ycf 24* gene product expression and/or
activity.

5. A method of identifying a compound that
inhibits the growth of an organism comprising
20 (i) contacting a test compound with the *ycf 24* gene
product, and
(ii) determining whether the test compound inhibits the
activity of or binds to the product, any such binding or
inhibition being indicative that the compound inhibits the
25 growth of the organism.

6. A method of identifying a compound that
~~inhibits the growth of an organism comprising~~
(i) contacting a test compound with a test construct
30 comprising a *ycf 24* promoter operably linked to a coding
sequence,
(ii) determining whether the test compound inhibits
expression driven by the promoter, any such inhibition
being indicative that the compound inhibits the growth of
35 the organism.

7. A method according to claim 5 or 6 in which the organism is a malaria parasite.

5 8. A compound identified by the method of any one of claims 5 to 7.

9. A compound according to claim 8 for use in the prevention or treatment of an infection by an organism.

10 10. A method of inhibiting the growth of an organism comprising contacting the organism ex vivo with a compound according to claim 8.

15 11. Use of a compound according to claim 8 for the manufacture of a medicament for the treatment of an infection by an organism.

20 12. A pharmaceutical composition comprising a compound as defined in any one of claims 1 to 3 or 8 and a pharmaceutically acceptable carrier or diluent.

25 13. A method of treating preventing or treating infection by a unicellular organism in a patient comprising administering to the patient an inhibitor as defined in any one of claims 1 to 3 or 8.

14. A method according to claim 13 in which the organism is a malaria parasite.

ABSTRACT

TREATMENT OF INFECTION

5

An inhibitor of *ycf 24* gene product expression and/or activity is used in a method of treatment of the human or animal body by therapy. In particular the inhibitor is used in a method of treatment of infection by an organism.

10. The organism may be a malaria parasite, such as *Plasmodium falciparum*.

The invention also provides a method of inhibiting the growth of an organism comprising contacting the organism ex vivo with an inhibitor of *ycf 24* gene product expression and/or activity.

The invention further provides a method of identifying a compound that inhibits the growth of an organism comprising

20 (i) contacting a test compound with the *ycf 24* gene product, and

(ii) determining whether the test compound inhibits the activity of or binds to the product, any such binding or inhibition being indicative that the compound inhibits the

25 growth of the organism.




Fig 1 1/1

THIS PAGE IS BLANK





Fig 2 2/2

PLS SEE 90:00:20
KINDLY
JAN 20 1960

THIS PAGE BLANK (USPTO)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

This Page Blank (uspto)